{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T01:01:48Z","timestamp":1791162108974,"version":"4.1.0"},"reference-count":35,"publisher":"Oxford University Press (OUP)","issue":"9","license":[{"start":{"date-parts":[[2013,7,23]],"date-time":"2013-07-23T00:00:00Z","timestamp":1374537600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2013,9,1]]},"abstract":"<jats:title>Learning Objectives<\/jats:title>\n                  <jats:p>Determine circumstances under which ovarian cancer patients would benefit from carboplatin plus pegylated liposomal doxorubicin rather than carboplatin plus paclitaxel. Compare and contrast efficacy and toxicity profiles of carboplatin plus pegylated liposomal doxorubicin versus carboplatin plus paclitaxel. Compare and contrast efficacy and toxicity profiles of single agent pegylated liposomal doxorubicin versus topotecan, gemcitabine, olaparib, patupilone, and canfosfamide.<\/jats:p>","DOI":"10.1634\/theoncologist.2013-0126","type":"journal-article","created":{"date-parts":[[2013,7,24]],"date-time":"2013-07-24T12:32:13Z","timestamp":1374669133000},"page":"1022-1031","source":"Crossref","is-referenced-by-count":57,"title":["The Role of Pegylated Liposomal Doxorubicin in Ovarian Cancer: A Meta-Analysis of Randomized Clinical Trials"],"prefix":"10.1093","volume":"18","author":[{"given":"Jean-Marie","family":"Gibson","sequence":"first","affiliation":[{"name":"Department of Immunotherapeutics and Biotechnology, Texas Tech University Health Sciences Center School of Pharmacy, Abilene, Texas, USA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saeed","family":"Alzghari","sequence":"additional","affiliation":[{"name":"Department of Immunotherapeutics and Biotechnology, Texas Tech University Health Sciences Center School of Pharmacy, Abilene, Texas, USA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chul","family":"Ahn","sequence":"additional","affiliation":[{"name":"Department of Clinical Sciences, University of Texas Southwestern Medical Center, Dallas, Texas, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Holly","family":"Trantham","sequence":"additional","affiliation":[{"name":"Department of Immunotherapeutics and Biotechnology, Texas Tech University Health Sciences Center School of Pharmacy, Abilene, Texas, USA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ninh M.","family":"La-Beck","sequence":"additional","affiliation":[{"name":"Department of Immunotherapeutics and Biotechnology, Texas Tech University Health Sciences Center School of Pharmacy, Abilene, Texas, USA;"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2013,7,23]]},"reference":[{"key":"2021122308451021000_B1","volume-title":"NCCN clinical practice guidelines in oncology (NCCN Guidelines): Ovarian cancer including fallopian tube cancer and primary peritoneal cancer","author":"Morgan","year":"2013"},{"key":"2021122308451021000_B2","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1186\/1756-9966-31-14","article-title":"Therapeutic strategies in epithelial ovarian cancer","volume":"31","author":"Kim","year":"2012","journal-title":"J Exp Clin Cancer Res"},{"key":"2021122308451021000_B3","doi-asserted-by":"crossref","first-page":"1320","DOI":"10.1093\/jnci\/djg036","article-title":"A randomized clinical trial of cisplatin\/paclitaxel versus carboplatin\/paclitaxel as first-line treatment of ovarian cancer","volume":"95","author":"Bois","year":"2003","journal-title":"J Natl Cancer Inst"},{"key":"2021122308451021000_B4","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1186\/1471-2407-6-5","article-title":"Residual neurotoxicity in ovarian cancer patients in clinical remission after first-line chemotherapy with carboplatin and paclitaxel: The Multicenter Italian Trial in Ovarian cancer (MITO-4) retrospective study","volume":"6","author":"Pignata","year":"2006","journal-title":"BMC Cancer"},{"key":"2021122308451021000_B5","first-page":"691","article-title":"Optimizing liposomes for delivery of chemotherapeutic agents to solid tumors","volume":"51","author":"Drummond","year":"1999","journal-title":"Pharmacol Rev"},{"key":"2021122308451021000_B6","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1097\/GRF.0b013e31824b9bc5","article-title":"A rational approach to the management of recurrent or persistent ovarian carcinoma","volume":"55","author":"Thigpen","year":"2012","journal-title":"Clin Obstet Gynecol"},{"key":"2021122308451021000_B7","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1586\/era.11.187","article-title":"Use of pegylated liposomal doxorubicin in the management of platinum-sensitive recurrent ovarian cancer: Current concepts","volume":"12","author":"Rakowski","year":"2012","journal-title":"Expert Rev Anticancer Ther"},{"key":"2021122308451021000_B8","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1038\/bjc.2012.307","article-title":"Final overall survival results of phase III GCIG CALYPSO trial of pegylated liposomal doxorubicin and carboplatin vs paclitaxel and carboplatin in platinum-sensitive ovarian cancer patients","volume":"107","author":"Wagner","year":"2012","journal-title":"Br J Cancer"},{"key":"2021122308451021000_B9","doi-asserted-by":"crossref","first-page":"3628","DOI":"10.1200\/JCO.2010.33.8566","article-title":"Carboplatin plus paclitaxel versus carboplatin plus pegylated liposomal doxorubicin as first-line treatment for patients with ovarian cancer: The MITO-2 randomized phase III trial","volume":"29","author":"Pignata","year":"2011","journal-title":"J Clin Oncol"},{"key":"2021122308451021000_B10","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1186\/1741-7015-8-3","article-title":"A randomized phase II study of carboplatin plus pegylated liposomal doxorubicin versus carboplatin plus paclitaxel in platinum sensitive ovarian cancer patients: A Hellenic Cooperative Oncology Group study","volume":"8","author":"Bafaloukos","year":"2010","journal-title":"BMC Med"},{"key":"2021122308451021000_B11","doi-asserted-by":"crossref","first-page":"2020","DOI":"10.1093\/annonc\/mdr583","article-title":"Health-related quality of life in recurrent platinum-sensitive ovarian cancer\u2014results from the CALYPSO trial","volume":"23","author":"Brundage","year":"2012","journal-title":"Ann Oncol"},{"key":"2021122308451021000_B12","doi-asserted-by":"crossref","first-page":"2531","DOI":"10.2165\/11207510-000000000-00000","article-title":"Pegylated liposomal doxorubicin: A review of its use in metastatic breast cancer, ovarian cancer, multiple myeloma and AIDS-related Kaposi's sarcoma","volume":"71","author":"Duggan","year":"2011","journal-title":"Drugs"},{"key":"2021122308451021000_B13","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ygyno.2004.07.011","article-title":"Long-term survival advantage for women treated with pegylated liposomal doxorubicin compared with topotecan in a phase 3 randomized study of recurrent and refractory epithelial ovarian cancer","volume":"95","author":"Gordon","year":"2004","journal-title":"Gynecol Oncol"},{"key":"2021122308451021000_B14","doi-asserted-by":"crossref","first-page":"3841","DOI":"10.1200\/JCO.2011.38.8082","article-title":"Randomized, open-label, phase III study comparing patupilone (EPO906) with pegylated liposomal doxorubicin in platinum-refractory or -resistant patients with recurrent epithelial ovarian, primary fallopian tube, or primary peritoneal cancer","volume":"30","author":"Colombo","year":"2012","journal-title":"J Clin Oncol"},{"key":"2021122308451021000_B15","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1200\/JCO.2007.13.6606","article-title":"Phase III trial of gemcitabine compared with pegylated liposomal doxorubicin in progressive or recurrent ovarian cancer","volume":"26","author":"Ferrandina","year":"2008","journal-title":"J Clin Oncol"},{"key":"2021122308451021000_B16","doi-asserted-by":"crossref","first-page":"2815","DOI":"10.1002\/(SICI)1097-0258(19981230)17:24<2815::AID-SIM110>3.0.CO;2-8","article-title":"Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints","volume":"17","author":"Parmar","year":"1998","journal-title":"Stat Med"},{"key":"2021122308451021000_B17","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/0197-2456(86)90046-2","article-title":"Meta-analysis in clinical trials","volume":"7","author":"DerSimonian","year":"1986","journal-title":"Control Clin Trials"},{"key":"2021122308451021000_B18","doi-asserted-by":"crossref","first-page":"3323","DOI":"10.1200\/JCO.2009.25.7519","article-title":"Pegylated liposomal doxorubicin and carboplatin compared with paclitaxel and carboplatin for patients with platinum-sensitive ovarian cancer in late relapse","volume":"28","author":"Pujade-Lauraine","year":"2010","journal-title":"J Clin Oncol"},{"key":"2021122308451021000_B19","volume-title":"Cochrane handbook for systematic reviews of interventions, version 5.1.0","author":"Higgins","year":"2011"},{"key":"2021122308451021000_B20","doi-asserted-by":"crossref","first-page":"2811","DOI":"10.1200\/JCO.2006.09.6735","article-title":"Randomized phase III trial of gemcitabine compared with pegylated liposomal doxorubicin in patients with platinum-resistant ovarian cancer","volume":"25","author":"Mutch","year":"2007","journal-title":"J Clin Oncol"},{"key":"2021122308451021000_B21","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1111\/IGC.0b013e3181daaf59","article-title":"Randomized phase III study of canfosfamide in combination with pegylated liposomal doxorubicin compared with pegylated liposomal doxorubicin alone in platinum-resistant ovarian cancer","volume":"20","author":"Vergote","year":"2010","journal-title":"Int J Gynecol Cancer"},{"key":"2021122308451021000_B22","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1093\/jnci\/djk091","article-title":"When you look matters: The effect of assessment schedule on progression-free survival","volume":"99","author":"Panageas","year":"2007","journal-title":"J Natl Cancer Inst"},{"key":"2021122308451021000_B23","doi-asserted-by":"crossref","first-page":"1030","DOI":"10.1200\/JCO.2011.38.7571","article-title":"Progression-free survival: Meaningful or simply measurable?","volume":"30","author":"Booth","year":"2012","journal-title":"J Clin Oncol"},{"key":"2021122308451021000_B24","doi-asserted-by":"crossref","first-page":"2666","DOI":"10.1056\/NEJMoa072113","article-title":"Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer","volume":"357","author":"Miller","year":"2007","journal-title":"N Engl J Med"},{"key":"2021122308451021000_B25","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1023\/A:1013172910858","article-title":"Possible mechanisms of acquired resistance to anti-angiogenic drugs: Implications for the use of combination therapy approaches","volume":"20","author":"Kerbel","year":"2001","journal-title":"Cancer Metastasis Rev"},{"key":"2021122308451021000_B26","doi-asserted-by":"crossref","first-page":"1430","DOI":"10.1093\/annonc\/mdg374","article-title":"Complement activation following first exposure to pegylated liposomal doxorubicin (Doxil): Possible role in hypersensitivity reactions","volume":"14","author":"Chanan-Khan","year":"2003","journal-title":"Ann Oncol"},{"key":"2021122308451021000_B27","first-page":"205","article-title":"Taxol reactions","volume":"23","author":"Price","year":"2002","journal-title":"Allergy Asthma Proc"},{"key":"2021122308451021000_B28","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1007\/s004320050297","article-title":"An effective and more convenient drug regimen for prophylaxis against paclitaxel-associated hypersensitivity reactions","volume":"125","author":"Markman","year":"1999","journal-title":"J Cancer Res Clin Oncol"},{"key":"2021122308451021000_B29","volume-title":"Doxil [product information]","year":"2012"},{"key":"2021122308451021000_B30","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1200\/JCO.1999.17.4.1141","article-title":"Clinical features of hypersensitivity reactions to carboplatin","volume":"17","author":"Markman","year":"1999","journal-title":"J Clin Oncol"},{"issue":"suppl 4","key":"2021122308451021000_B31","doi-asserted-by":"crossref","first-page":"iv45","DOI":"10.1093\/neuonc\/nos203","article-title":"Peripheral neuropathies from chemotherapeutics and targeted agents: Diagnosis, treatment, and prevention","volume":"14","author":"Grisold","year":"2012","journal-title":"Neuro Oncol"},{"key":"2021122308451021000_B32","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1111\/ecc.12056","article-title":"The experience of chemotherapy-induced alopecia for Australian women with ovarian cancer","volume":"22","author":"Jayde","year":"2013","journal-title":"Eur J Cancer Care (Engl)"},{"key":"2021122308451021000_B33","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1046\/j.1523-5394.2001.96007.x","article-title":"Psychological sequelae and alopecia among women with cancer","volume":"9","author":"McGarvey","year":"2001","journal-title":"Cancer Pract"},{"key":"2021122308451021000_B34","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.1200\/JCO.2008.19.1684","article-title":"Evaluation of new platinum-based treatment regimens in advanced-stage ovarian cancer: A phase III trial of the Gynecologic Cancer Intergroup","volume":"27","author":"Bookman","year":"2009","journal-title":"J Clin Oncol"},{"key":"2021122308451021000_B35","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1200\/JCO.2011.36.9215","article-title":"Phase II, open-label, randomized, multicenter study comparing the efficacy and safety of olaparib, a poly(ADP-ribose) polymerase inhibitor, and pegylated liposomal doxorubicin in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer","volume":"30","author":"Kaye","year":"2012","journal-title":"J Clin Oncol"}],"container-title":["The Oncologist"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1634\/theoncologist.2013-0126","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1634\/theoncologist.2013-0126","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/18\/9\/1022\/41859608\/oncolo_18_9_1022.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/18\/9\/1022\/41859608\/oncolo_18_9_1022.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,12,23]],"date-time":"2021-12-23T20:24:30Z","timestamp":1640291070000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/oncolo\/article\/18\/9\/1022\/6410310"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,7,23]]},"references-count":35,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2013,7,23]]},"published-print":{"date-parts":[[2013,9,1]]}},"URL":"https:\/\/doi.org\/10.1634\/theoncologist.2013-0126","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.718046276.793483428","asserted-by":"object"}]},"ISSN":["1083-7159","1549-490X"],"issn-type":[{"value":"1083-7159","type":"print"},{"value":"1549-490X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2013,9,1]]},"published":{"date-parts":[[2013,7,23]]}}}